XML 25 R14.htm IDEA: XBRL DOCUMENT v3.25.1

SEGMENT INFORMATION

6 Months Ended

Mar. 31, 2025

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE H – SEGMENT INFORMATION

As detailed in Note B above, the Company has three reportable segments: (1) Therapeutic DNA Production Services; (2) MDx Testing Services; and (3) DNA Tagging and Security Products and Services. Resources are allocated by our CEO, COO, CFO and CLO whom, collectively, the Company has determined to be our CODM.

Information regarding operations by segment for the three-month period ended March 31, 2025 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Therapeutic DNA

​

MDx Testing

​

DNA Tagging and

​

​

​

Production

Services and Kits

Security Products

Consolidated

Revenues:

​

​

​

​

Product revenues

​

$

419,412

​

$

—

​

$

129,226

​

$

548,638

Service revenues

​

47,797

​

—

​

166,387

​

$

214,184

Clinical laboratory service revenues

​

—

​

221,272

​

—

​

$

221,272

Less intersegment revenues

​

—

​

(720)

​

—

​

$

(720)

Total revenues

​

$

467,209

​

$

220,552

​

$

295,613

​

$

983,374

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross profit

​

$

290,735

​

$

(52,283)

​

$

132,395

​

$

370,847

​

​

​

​

​

​

​

​

​

​

​

​

​

Segment operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

Selling, general and administrative

​

$

1,053,968

​

$

298,839

​

$

329,904

​

$

1,682,711

Research and development

​

​

652,473

​

​

73,129

​

​

60,127

​

​

785,729

Total segment operating expenses

​

$

1,706,441

​

$

371,968

​

$

390,031

​

$

2,468,440

Loss from segment operations (a)

​

$

(1,415,706)

​

$

(424,251)

​

$

(257,636)

​

$

(2,097,593)

​

Information regarding operations by segment for the three-month period ended March 31, 2024 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Therapeutic DNA

​

MDx Testing

​

DNA Tagging and

​

​

​

Production

Services and Kits

Security Products

Consolidated

Revenues:

​

​

​

​

Product revenues

​

$

258,152

​

$

—

​

$

134,973

​

$

393,125

Service revenues

​

65,200

​

—

​

140,286

​

205,486

Clinical laboratory service revenues

​

—

​

335,580

​

—

​

335,580

Less intersegment revenues

​

—

​

(4,560)

​

—

​

(4,560)

Total revenues

​

​

323,352

​

​

331,020

​

​

275,259

​

​

929,631

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross profit

​

​

190,588

​

​

18,515

​

​

86,548

​

​

295,651

​

​

​

​

​

​

​

​

​

​

​

​

​

Segment operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

Selling, general and administrative

​

$

778,297

​

$

246,839

​

$

371,887

​

$

1,397,023

Research and development

​

​

577,740

​

​

70,267

​

​

214,713

​

​

862,720

Total segment operating expenses

​

$

1,356,037

​

$

317,106

​

$

586,600

​

$

2,259,743

Loss from segment operations (a)

​

​

(1,165,449)

​

​

(298,591)

​

​

(500,052)

​

​

(1,964,092)

​

​

NOTE H – SEGMENT INFORMATION, continued

Information regarding operations by segment for the six-month period ended March 31, 2025 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Therapeutic DNA

​

MDx Testing

​

DNA Tagging and

​

​

Production

Services and Kits

Security Products

Consolidated

Revenues:

​

​

​

​

Product revenues

$

507,408

$

—

$

537,077

$

1,044,485

Service revenues

​

​

107,242

​

​

—

​

​

481,386

​

$

588,628

Clinical laboratory service revenues

​

​

—

​

​

548,438

​

​

—

​

$

548,438

Less intersegment revenues

​

​

—

​

​

(1,560)

​

​

—

​

$

(1,560)

Total revenues

$

614,650

$

546,878

$

1,018,463

$

2,179,991

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross profit

$

403,233

$

1,963

$

649,758

$

1,054,954

​

​

​

​

​

​

​

​

​

​

​

​

​

Segment operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

Selling, general and administrative

​

$

1,856,769

​

$

551,924

​

$

1,038,060

​

$

3,446,753

Research and development

​

​

1,424,798

​

​

136,766

​

​

197,776

​

​

1,759,340

Total segment operating expenses

​

$

3,281,567

​

$

688,690

​

$

1,235,836

​

$

5,206,093

(Loss) income from segment operations (a)

$

(2,878,334)

$

(686,727)

$

(586,078)

$

(4,151,139)

​

Information regarding operations by segment for the six-month period ended March 31, 2024 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Therapeutic DNA

​

MDx Testing

​

DNA Tagging and

​

​

Production

Services and Kits

Security Products

Consolidated

Revenues:

​

​

​

​

Product revenues

$

258,152

$

—

$

442,290

$

700,442

Service revenues

​

​

142,735

​

​

—

​

​

309,898

​

​

452,633

Clinical laboratory service revenues

​

​

—

​

​

678,320

​

​

—

​

​

678,320

Less intersegment revenues

​

​

—

​

​

(10,600)

​

​

—

​

​

(10,600)

Total revenues

$

400,887

$

667,720

$

752,188

$

1,820,795

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross profit

$

268,123

$

(44,443)

$

303,068

$

526,748

​

​

​

​

​

​

​

​

​

​

​

​

​

Segment operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

Selling, general and administrative

​

$

1,518,582

​

$

605,516

​

$

1,153,357

​

$

3,277,455

Research and development

​

​

1,174,036

​

​

145,144

​

​

434,066

​

​

1,753,246

Total segment operating expenses

​

$

2,692,618

​

$

750,660

​

$

1,587,423

​

$

5,030,701

(Loss) income from segment operations (a)

$

(2,424,495)

$

(795,103)

$

(1,284,355)

$

(4,503,953)

​

​

NOTE H – SEGMENT INFORMATION, continued

Reconciliation of loss from segment operations to Corporate loss for the three-month periods ended March 31, 2025 and 2024 is as follows:

​

​	​	​	​	​	​	​
​	​	March 31,
​		2025			2024
Loss from operations of reportable segments	​	$	(2,097,593)	​	$	(1,964,092)
General corporate expenses (b)	​		(1,364,202)	​		(1,653,659)
Interest income	​		60,340	​		15,352
Unrealized gain on change in fair value of warrants classified as a liability	​		68,430	​		1,765,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification	​	​	—	​	​	(394,000)
Transaction costs allocated to warrant liabilities	​	​	—	​	​	(633,198)
Loss on issuance of warrants	​	​	—	​	​	(1,633,767)
Other (expense) income, net	​		(3,095)	​		4,581
Consolidated loss before provision for income taxes	​	$	(3,336,120)	​	$	(4,493,783)

​

Reconciliation of loss from segment operations to Corporate loss for the six-month periods ended March 31, 2025 and 2024 is as follows:

​	​	​	​	​	​	​
​	​	March 31,
​		2025			2024
Loss from operations of reportable segments		$	(4,151,139)		$	(4,503,953)
General corporate expenses (b)	​	​	(2,274,657)	​	​	(2,902,865)
Interest income	​	​	131,780	​	​	48,676
Unrealized gain on change in fair value of warrants classified as a liability	​	​	312,430	​	​	4,404,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification		​	—		​	(394,000)
Transaction costs allocated to warrant liabilities		​	—		​	(633,198)
Loss on issuance of warrants	​	​	—	​	​	(1,633,767)
Other (expense) income, net	​	​	(23,247)	​	​	(8,957)
Consolidated loss before provision for income taxes	​	$	(6,004,833)	​	$	(5,624,064)

(a) Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b) General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Name:	us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration